Zimmer Biomet (ZBH) Stock Forecast & Price Target

$102.00 +2.08 (+2.08%)

Closing price 10/17/2025 03:59 PM Eastern

Extended Trading

$101.93 -0.07 (-0.07%)

As of 10/17/2025 07:59 PM Eastern

Compare

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold

Based on 20 Analyst Ratings

Sell
2

Hold
8

Buy
10

Based on 20 Wall Street analysts who have issued ratings for Zimmer Biomet in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 2 have given a sell rating, 8 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for ZBH.

Consensus Price Target

$111.94
9.75% Upside

According to the 20 analysts' twelve-month price targets for Zimmer Biomet, the average price target is $111.94. The highest price target for ZBH is $135.00, while the lowest price target for ZBH is $95.00. The average price target represents a forecasted upside of 9.75% from the current price of $102.00.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ZBH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZBH Analyst Ratings Over Time

Type	Current Forecast 10/18/24 to 10/18/25	1 Month Ago 9/18/24 to 9/18/25	3 Months Ago 7/20/24 to 7/20/25	1 Year Ago 10/19/23 to 10/18/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)
Hold	8 Hold rating(s)	7 Hold rating(s)	9 Hold rating(s)	12 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$111.94	$112.06	$111.39	$123.74
Forecasted Upside	9.75% Upside	11.89% Upside	19.54% Upside	16.39% Upside
Consensus Rating	Hold	Moderate Buy	Hold	Hold

ZBH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zimmer Biomet Stock vs. The Competition

Type	Zimmer Biomet	Medical Companies	S&P 500
Consensus Rating Score	2.45	2.33	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	9.75% Upside	1,357.67% Upside	13.60% Upside
News Sentiment Rating	Positive News See Recent ZBH News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/13/2025	BTIG Research 2 of 5 stars	Ryan Zimmerman 5 of 5 stars	Boost Target	Buy	$118.00 ➝ $122.00	+28.71%
10/10/2025	Royal Bank Of Canada 3 of 5 stars	Shagun Singh Not Rated	Set Target		$111.00	+16.07%
10/8/2025	Weiss Ratings 0 of 5 stars		Reiterated Rating	Hold (C-)
10/7/2025	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	In-Line	$106.00 ➝ $104.00	+5.19%
9/19/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$115.00 ➝ $118.00	+17.36%
9/18/2025	Redburn Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ed Ridley-Day Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$130.00	+29.92%
9/18/2025	Rothschild Redb Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
9/18/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ed Ridley-Day Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$130.00	+30.21%
8/8/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sell	$91.00 ➝ $96.00	-1.71%
8/8/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$104.00 ➝ $113.00	+15.02%

8/7/2025	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
5/12/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$115.00 ➝ $101.00	+2.26%
5/7/2025	JMP Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Outperform	$140.00 ➝ $125.00	+32.72%
5/6/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$101.00	+7.08%
5/6/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$120.00 ➝ $104.00	+14.50%
5/6/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cecilia Furlong Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$115.00 ➝ $95.00	+4.11%
5/6/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$128.00 ➝ $105.00	+15.83%
5/6/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$113.00 ➝ $98.00	+8.66%
5/6/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeff Johnson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$130.00 ➝ $115.00	+27.29%
2/10/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Underweight	$118.00 ➝ $112.00	+10.88%
2/7/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
10/15/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$145.00 ➝ $135.00	+29.93%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Peer Perform
9/6/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Hold	$143.00 ➝ $119.00	+13.61%
7/10/2024	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$134.00 ➝ $120.00	+12.25%
7/1/2024	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. O'brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$140.00 ➝ $115.00	+5.96%
5/21/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+25.89%
10/20/2023	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Neutral	$120.00	+14.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:48 AM ET.

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 15, 2025. Please send any questions or comments about these Zimmer Biomet pros and cons to contact@marketbeat.com.

Zimmer Biomet
Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

The current stock price is around $98.87, which is near the lower end of its 1-year range, suggesting potential for growth.
Zimmer Biomet Holdings, Inc. reported a strong quarterly earnings performance, with earnings per share exceeding analysts' expectations, indicating robust financial health.
The company has shown a year-over-year revenue increase of 7.0%, reflecting its ability to grow and adapt in the medical equipment sector.
With a market capitalization of approximately $19.59 billion, Zimmer Biomet Holdings, Inc. is a significant player in the industry, which can provide stability to investors.
The firm has a relatively low debt-to-equity ratio of 0.54, suggesting a conservative approach to leveraging, which can be appealing to risk-averse investors.

Zimmer Biomet
Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

The stock has experienced a decrease in trading volume, with only 402,488 shares exchanged recently compared to an average of 1,928,445, which may indicate reduced investor interest.
Analysts have recently lowered the price target for Zimmer Biomet Holdings, Inc. from $106.00 to $104.00, suggesting a more cautious outlook on the stock's performance.
The company has a quick ratio of 0.96, which is below 1, indicating potential liquidity issues that could affect its ability to meet short-term obligations.
Despite a positive earnings report, the overall market sentiment may be influenced by broader economic conditions, which could impact stock performance.
With a beta of 0.67, the stock is less volatile than the market, which may limit potential high returns for investors seeking aggressive growth.

ZBH Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Zimmer Biomet is $111.94, with a high forecast of $135.00 and a low forecast of $95.00.
: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last twelve months. There are currently 2 sell ratings, 8 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.
: According to analysts, Zimmer Biomet's stock has a predicted upside of 9.75% based on their 12-month stock forecasts.
: Over the previous 90 days, Zimmer Biomet's stock had 1 upgrade by analysts.
: Zimmer Biomet has been rated by research analysts at BTIG Research, Evercore ISI, Raymond James Financial, Redburn Partners, Roth Capital, Rothschild & Co Redburn, Rothschild Redb, Royal Bank Of Canada, Stifel Nicolaus, UBS Group, and Weiss Ratings in the past 90 days.
: Analysts like Zimmer Biomet more than other "medical" companies. The consensus rating score for Zimmer Biomet is 2.45 while the average consensus rating score for "medical" companies is 2.33. Learn more on how ZBH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ZBH) was last updated on 10/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Stock Forecast & Price Target